Using Video Decision-Support Tools to Facilitate End-of-Life Discussions With Patients
Research shows that although most Americans, about 80%, would prefer to die at home, only 20% actually do; 60% die in acute care hospitals, and 20% die in nursing homes...
Should We Treat Rising PSA in Men With Castrate Androgen Levels?
In rapid succession, the SPARTAN study results were presented at the 2018 Genitourinary Cancers Symposium, the data were published in The New England Journal of Medicine...
Nilotinib Label Updated to Provide Treatment Discontinuation Recommendations for CML With Sustained Molecular Response
On December 22, 2017, the product label for nilotinib was updated to include information on nilotinib discontinuation, postdiscontinuation monitoring, and guidance for treatment...
USPSTF Recommendations on PSA-Based Screening for Prostate Cancer
As reported in JAMA, the US Preventive Services Task Force (USPSTF) has issued updated recommendations on prostate-specific antigen (PSA)-based screening for prostate cancer...
Long-Term Follow-up of Women With Vaginal and Cervical Clear Cell Adenocarcinoma Associated With DES Exposure
In a letter to the editor of The New England Journal of Medicine, Huo et al described long-term outcomes of women with vaginal and cervical clear cell adenocarcinoma associated...
More Top Stories
AACR Welcomes New Leadership at 2018 Annual Meeting
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) welcomes Elizabeth M. Jaffee, MD, Deputy Director for the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Associate Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy, as President of AACR for 2018–2019....
USPSTF Recommendations on PSA-Based Screening for Prostate Cancer
As reported in JAMA, the US Preventive Services Task Force (USPSTF) has issued updated recommendations on prostate-specific antigen (PSA)-based screening for prostate cancer. To inform the recommendations, the USPSTF reviewed evidence on benefits and harms of PSA-based screening and treatment of...
Microenvironment Heterogeneity May Contribute to Lack of Immunotherapy Success in High-Grade Serous Ovarian Cancer
INTER- AND INTRAPATIENT heterogeneity of the tumor microenvironment may explain the limited success of checkpoint blockade thus far observed in patients with advanced high-grade serous ovarian cancer, according to Paulina Cybulska, MD, MSc, of Memorial Sloan Kettering Cancer Center in New York. ...
Afatinib in Previously Untreated Metastatic NSCLC With Nonresistant EGFR Mutations
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 12, 2018, afatinib (Gilotrif) was approved...
CXCR4 Antagonist Plus Eribulin in HER2-Negative Metastatic Breast Cancer
Findings in a phase I trial reported in The Lancet Oncology by Pernas et al indicate activity of the combination of the CXCR4 chemokine receptor antagonist balixafortide plus eribulin in previously treated HER2-negative metastatic breast cancer. The CXCR4–stromal cell-derived factor-1α...
Adjuvant Pembrolizumab Improves Relapse-Free Survival in High-Risk Stage III Melanoma
ADJUVANT THERAPY with pembrolizumab (Keytruda) significantly prolonged recurrence-free survival compared with placebo for patients with resected high-risk stage III melanoma, according to the results of the EORTC 1325/KEYNOTE-054 trial.1 Patients who received pembrolizumab had a 43% reduction in...
Long-Term Follow-up of Women With Vaginal and Cervical Clear Cell Adenocarcinoma Associated With DES Exposure
In a letter to the editor of The New England Journal of Medicine, Huo et al described long-term outcomes of women with vaginal and cervical clear cell adenocarcinoma associated with prenatal exposure to the synthetic nonsteroidal estrogen diethylstilbestrol (DES). As noted by the authors, women...
Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial
